PMCPA PRESS RELEASE 4 June 2025 - Case ruled in breach of Clause 2
THERAMEX has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Press Release 04 June 2025
THERAMEX – Case/0270/08/24 – Alleged promotion of an unauthorised indication for linzagolix
For promoting Yselty (linzagolix) outside the terms of its marketing authorisation at a scientific congress dedicated to endometriosis, Theramex was ruled in breach of the following clauses of the 2021 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 11.2 - Promoting a medicine for an unlicensed indication
The case report is available at www.pmcpa.org.uk.
Ends
Notes to Editors:
Notes to Editors:
The advertisement will appear in the BMJ and the Nursing Standard in June 2025.
Media Contacts:
For more information contact Alex Fell afell@pmcpa.org.uk 0207 747 8878
The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of the ABPI. The Code covers the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines.
If you have any concerns about the activities of pharmaceutical companies in this regard, please contact the PMCPA at 2nd Floor, Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB, email: complaints@pmcpa.org.uk, or visit www.pmcpa.org.uk/complaints-procedure/make-a-complaint.
The Code and other information, including details about ongoing cases, can be found on the PMCPA website: www.pmcpa.org.uk.
The PMCPA is a division of the ABPI which is a company limited by guarantee registered in England & Wales no 09826787. Registered office 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.